CurveBeam AI Ltd. · ASX:CVB
CurveBeam AI — NWR Healthcare Technology Lunch (November 2026)
17 slides from CurveBeam AI's conference presentation, Nov 19, 2026
Slide 1: CurveBeam AI to present at NWR Healthcare Technology Lunch
ASX ANNOUNCEMENT For personal use only ASX: CVB 19 November 2026 CurveBeam AI to present at NWR Healthcare Technology Lunch Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB “CurveBeam AI” or the “Company”), a fully integrated developer and manufacturer of point-of-care s
Slide 2: NWR Healthcare Technology Lunch - CurveBeam AI Investor Deck
rsonal use only NWR Healthcare Technology Lunch CurveBeam AI Investor Deck (ASX:CVB) Thursday November 19th 2026 Point of Care (PoC) WBCT with future bone quality assessment
Slide 3: Disclaimer
DISCLAIMER THIS PRESENTATION IS NOT FOR RELEASE TO U.S. WIRE SERVICES OR IN ANY OTHER JURISDICTION (and is not) an indication of CurveBeam’s views on future performance or condition. Past performance cannot be WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT, AND rel
Slide 4: CurveBeam AI Company Highlights
C U R V E B E A M A I C O M PA N Y H I G H L I G H T S • FDA cleared | TGA & CE mark | NMPA o U.S. & German reimbursement in place1 rsonal use only • 200+ weight bearing CT units (WBCT) globally • USA co-marketing & distribution agreement with Stryker Corp. Foot & Ankle (NYSE:SYK) Combining Weight B
Slide 5: The Problem / The Solution
THE PROBLEM THE SOLUTION Traditional CT Scans don’t show the joint under its natural weight rsonal use only Traditional CT Scan HiRise CT Scan (i.e. non-weight bearing) (i.e. weight bearing & non-weight bearing) TRADITIONAL CT HIRISE SCANNER SCANNER Additional Challenges: Additional Benefits: Can
Slide 6: Product Portfolio
PRODUCT PORTFOLIO Lead Product rsonal use only HiRise CT Scan pedCAT® Evo InReach® (i.e. weight bearing & non-weight bearing) (i.e. weight bearing) • FDA cleared | CE Mark | TGA • FDA targeted 2027 • FDA cleared | CE Mark | TGA • Foot, ankle, hip, knee, joint • Foot and ankle • Extremity cone beam C
Slide 7: Why Weight Bearing CT Matters: Workflow Perspective
Why Weight Bearing CT Matters: Workflow Perspective Patient Journey: Current State Patient Journey: With HiRiseTM rsonal use only Surgeon CT Scan sent Surgeon BMD result refers patient to surgeon refers patient sent to for CT (1-7 days) over 65 for surgeon Surgery Plan Surgery Plan imaging bone dens
Slide 8: Global Growth Strategy
G L O B A L G R O W T H S T R AT E G Y Successful placement of HiRise devices four continents rsonal use only NORTH AMERICA Operations HQ (Penn.) EUROPE 4 FTE Sales reps 6 Distributors GREATER CHINA Marketing Team 2 FTE Sales reps Recently announced Partner Management (Stryker) 20+ HiRise partnershi
Slide 9: Greater China Market Opportunity
G R E AT E R C H I N A M A R K E T O P P O R T U N I T Y Chinese Partner Opens up China, SE ASIA and Large Addressable Market rsonal use only Further Milestone Payments ✓ China NMPA approval for HiRise $1m investment $10m equity investment by CVB’s $1m investment & ✓ Wego first 10 HiRise orders Asia
Slide 10: Business Model
BUSINESS MODEL U.S. Reimbursement Coding in place rsonal use only 1x Sale Recurring revenue opportunity Capital Equipment Bone Mineral Density (“BMD”) Testing HiRise SaaS Model o USD$410k - $465k per unit1 (A$585K – A$664K) o Expand BMD test capability to the surgeon group practice o Target customer
Slide 11: Enhanced HiRise Validation in Knee/Hip
ENHANCED HIRISE VALIDATION IN KNEE/HIP What is a robotic cut guide Validation ongoing with multiple suppliers of knee products rsonal use only • CVB working to validate HiRise for multiple knee non-robotic surgery options – 1) Restor3d/Conformis, 2) Medacta Knee Osteotomy PSI1,3) Newclip - knee Oste
Slide 12: Robotic Market - Drives CT Dependence
ROBOTIC MARKET – DRIVES CT DEPENDENCE 1. Robotic system adoption for orthopedics continues at a steady pace with ~ 25% of US operating rooms having access to a robot - Source Global Data 2023 2. Stryker MAKO, J&J VELYS, Zimmer ROSA and S&N CORI – held 85% of the market - Source Global Data 2023 3. M
Slide 13: BoneVue BMD MDCT FDA Cleared
BONEVUE BMD MDCT FDA CLEARED rsonal use only 2nd Step Multidetector CT (MDCT) clearance • September 2026, CVB U.S. FDA (FDA) 510(k) clearance for its first product for CT Bone Mineral Density (BMD) for multidetector CT (MDCT) • Following feedback from the FDA during the 510(k)-review process, the Co
Slide 14: Near Term Targeted Milestones
N E A R T E R M TA R G E T E D M I L E S TO N E S A number of near-term value-driving operational & commercial milestone targets rsonal use only 1 First $4m License Payment received from China Partner Q1 CY26 Chinese FDA (NMPA) approval for US manufactured HiRise 2 & further $1m Wego Equity Investme
Slide 15: Competition
COMPETITION Compact but non-natural weight bearing Lacking a one size fits all approach rsonal use only • Size of competitor devices not conducive to surgeon setting PlanMed Verity • Many still are limited by multi detector computed tomography (MDCT) and the high-level radiation scans Example of Lar
Slide 16: Board of Directors
BOARD OF DIRECTORS Experienced and personally invested Board rsonal use only ROBERT LILLEY GREGORY BROWN PATRICK FISHER DANIEL PRYOR ARUN SINGH DR YU PENG Non-Executive Chairman, Chief Executive Officer, Non-Executive Director Non-Executive Director Executive Director, Executive Director, BA (Yale)
Slide 17: Risk Factors
RISK FACTORS The following is a summary of the material business risks of the Group (which are not listed in order of importance or likelihood). These risks may adversely impact on the Group’s financial and operating performance and prospects. Additional business risks can be found in the Group’s An
CurveBeam AI — NWR Healthcare Technology Lunch (November 2026) on 6ix